ClinicalTrials.gg
CompletedNCT02222922Updated Dec 17, 2020Results posted

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

A Phase 1 interventional study of PF-06647020 Q3W and fluconazole in Neoplasms, sponsored by Pfizer. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
138
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

02

Conditions studied

  • Neoplasms

Keywords

  • ADC
  • PF-06647020
  • solid tumors
  • tumors
  • neoplasm metastasis
  • TNBC
  • triple negative breast cancer
  • NSCLC
  • non small cell lung cancer
  • advanced metastatic breast cancer
  • ovarian cancer
  • OVCA
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 138 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Q2W Inclusion Criteria:

  • Diagnosis of platinum resistant or OVCA having received 2 or fewer prior lines, or recurrent advanced NSCLC having received 3 or fewer prior lines
  • Performance Status of 0, 1, or 2
  • Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

  • OVCA pts excluded with any of the following: non-epithelial, including malignant mixed mullerian tumors, unresolved bowel obstruction
  • requiring
  • Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
  • Active and bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

  • Diagnosis of solid tumor that is advanced/ and resistant to standard therapy or for whom no standard therapy is available
  • Performance Status of 0 or 1
  • Adequate bone marrow, kidney, and liver function
  • Part 2 includes ovarian cancer, target expressing triple negative breast cancer and non small cell lung cancer patients

Q3W Exclusion Criteria:

  • OVCA pts excluded with any of the following: non-epithelial, including malignant mixed mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease, unresolved bowel obstruction
  • Brain metastases requiring steroids
  • Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
  • Active and clinically significant bacterial, fungal, or viral infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    PF-06647020 Q3W

    Investigational drug infused over 60 minutes once every 21 days.

    Drug: PF-06647020 Q3W

  • Experimental
    Drug-drug interaction (DDI)

    PF-06647020 combined with fluconazole

    Drug: fluconazole

  • Experimental
    PF-06647020 Q2W

    Investigational drug infused over 60 minutes once every 14 days (28 day cycle)

    Drug: PF-06647020 Q2W

  • Experimental
    PF-06647020 combined with Avelumab

    PF-06647020 combined with Avelumab administered by infusion

    Drug: PF-06647020 combined with Avelumab

Interventions

  • DrugPF-06647020 Q3W

    Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined. Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.

  • combination drug used for drug-drug interaction sub-study

  • DrugPF-06647020 Q2W

    Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined. Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.

  • DrugPF-06647020 combined with Avelumab

    Drug page: Avelumab

    Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen

    A DLT was any of the following adverse events(AEs) in the first cycle of treatment (within 21 days of first dose or until participant received second infusion if there were treatment delays). (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 anemia; Grade \>=3 thrombocytopenia with clinically significant bleeding. (2) Hepatic, including Grade \>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>=3.0 x upper limit of normal (ULN) concurrent with elevation in bilirubin \>=2.0 x ULN; (3) Grade \>=3 non-hematologic, non-hepatic major organ toxicities; delayed by \>2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. A participant was on study for at least 21 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 21 days.

    Time frame: First Cycle, Day 1 up to Day 21

  2. Number of Participants With Treatment-Emergent Adverse Events (AEs) - Q3W Regimen (All-Causality)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.

    Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)

  3. Number of Participants With Treatment-Emergent AEs - Q3W Regimen (Treatment-Related)

    A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.

    Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)

  4. Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q3W Regimen (All-Causality and Treatment-Related)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication. All AEs were graded by the investigator according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.

    Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)

  5. Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q3W Regimen

    Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: absolute neutrophils, lymphopenia, white blood cell, anemia, platelets.

    Time frame: From baseline to end of treatment (approximately 32 months).

  6. Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q3W Regimen

    Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: hypokalemia, hypophosphatemia, aspartate aminotransferase, hyperglycemia, alkaline phosphatase, hyponatremia, alanine aminotransferase, hypoalbuminemia, total bilirubin, hypercalcemia, hypomagnesemia , creatinine, gamma glutamyl transferase, hypocalcemia.

    Time frame: From baseline to end of treatment (approximately 32 months).

  7. Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q3W Regimen

    Participants who experienced urinalysis laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with urinalysis laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above.

    Time frame: From baseline to end of treatment (approximately 32 months).

  8. Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q3W Regimen

    Participants who experienced coagulation laboratory test abnormalities were summarized according to worst toxicity grade observed for each coagulation laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with coagulation laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameter: partial thromboplastin time.

    Time frame: From baseline to end of treatment (approximately 32 months).

  9. Number of Participants With DLTs - Q2W Regimen

    A DLT was any of the following AEs in the first cycle of treatment (within 28 days of first dose or until participant received second infusion if there were treatment delayed) in the single agent dose escalation. (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 thrombocytopenia; treatment delay \>14 days because of hematologic AE; (2) Hepatic: including Grade\>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; ALT or AST\>=3.0 x ULN concurrent with elevation in bilirubin\>=2.0 x ULN; (3) Grade \>=3 non-hematologic, non-hepatic major organ toxicities; delayed by \>2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. Grade \>=3 headache lasting \>48 hours in presence of supportive care. A participant was on study for at least 28 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 28 days.

    Time frame: First cycle, Day 1 up to Day 28

  10. Number of Participants With Treatment-Emergent AEs - Q2W Regimen (All-Causality)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.

    Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)

  11. Number of Participants With Treatment-Emergent AEs - Q2W Regimen (Treatment-Related)

    A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.

    Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)

  12. Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q2W Regimen (All-Causality and Treatment-Related)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication. All AEs were graded by the investigator according to the NCI CTCAE version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.

    Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)

  13. Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q2W Regimen

    Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: absolute neutrophils, lymphopenia, white blood cell, anemia.

    Time frame: From baseline to end of treatment (approximately 19 months).

  14. Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q2W Regimen

    Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: hypokalemia, hyponatremia, hypomagnesemia, hypoalbuminemia, hypocalcemia, hypophosphatemia, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase.

    Time frame: From baseline to end of treatment (approximately 19 months).

  15. Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q2W Regimen

    Participants who experienced urinalysis laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with urinalysis laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above.

    Time frame: Baseline and Day 1 of Cycle 1

  16. Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q2W Regimen

    Participants who experienced coagulation laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with coagulation laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameter: prothrombin time international normalized ratio.

    Time frame: From baseline to end of treatment (approximately 19 months).

Secondary outcomes

  1. Area Under the Concentration-Time Profile From Time 0 to Time Tau (AUCtau) for PF-06647020 - Q3W Regimen

    Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06647020 was determined using linear/log trapezoidal method.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  2. Maximum Observed Serum Concentration (Cmax) for PF-06647020 -Q3W Regimen

    Cmax is maximum observed serum concentration. Cmax for PF-06647020 was observed directly from data.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  3. Clearance (CL) for PF-06647020 - Q3W Regimen

    Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance for PF-06647020 was calculated as dose/AUCinf for single dose and dose/AUCtau for multiple dose, where AUCinf was the area under the serum concentration-time profile from time 0 extrapolated to infinite time and AUCtau was the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing).

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  4. Volume of Distribution at Steady State (Vss) for PF-06647020 - Q3W Regimen

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  5. Terminal Half-Life (t1/2) for PF-06647020 - Q3W Regimen

    Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  6. Observed Accumulation Ratio (Rac) for PF-06647020 - Q3W Regimen

    Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

    Time frame: pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).

  7. Time for Cmax (Tmax) for PF-06647020 - Q3W Regimen

    Tmax is the time for Cmax. Tmax for PF-06647020 was observed directly from data as time of first occurrence.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  8. Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for PF-06647020 - Q3W Regimen

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06647020 was determined using linear/log trapezoidal method.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  9. Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06647020 - Q3W Regimen

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for PF-06647020 was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  10. AUCtau for PF-06380101 - Q3W Regimen

    Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06380101 was determined using linear/log trapezoidal method.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  11. Cmax for PF-06380101 - Q3W Regimen

    Cmax is maximum observed serum concentration. Cmax for PF-06380101 was observed directly from data.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  12. t1/2 for PF-06380101 - Q3W Regimen

    Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  13. Rac for PF-06380101 - Q3W Regimen

    Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

    Time frame: pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).

  14. Tmax for PF-06380101 - Q3W Regimen

    Tmax is the time for Cmax. Tmax for PF-06380101 was observed directly from data as time of first occurrence.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  15. AUClast for PF-06380101 - Q3W Regimen

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06380101 was determined using linear/log trapezoidal method.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  16. AUCinf for PF-06380101 - Q3W Regimen

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for PF-06380101 was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  17. AUCtau for hu6M024 mAb - Q3W Regimen

    Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for hu6M024 mAb was determined using linear/log trapezoidal method.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  18. Cmax for hu6M024 mAb - Q3W Regimen

    Cmax is maximum observed serum concentration. Cmax for hu6M024 mAb was observed directly from data.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  19. t1/2 for hu6M024 mAb - Q3W Regimen

    Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  20. Rac for hu6M024 mAb - Q3W Regimen

    Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

    Time frame: pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).

  21. Tmax for hu6M024 mAb - Q3W Regimen

    Tmax is the time for Cmax. Tmax for hu6M024 mAb was observed directly from data as time of first occurrence.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  22. AUClast for hu6M024 mAb - Q3W Regimen

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for hu6M024 mAb was determined using linear/log trapezoidal method.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  23. AUCinf for hu6M024 mAb - Q3W Regimen

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for hu6M024 mAb was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).

  24. Number of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibody (NAb) of PF-06647020 - Q3W Regimen

    To evaluate the immunogenicity as measured by presence of ADA and NAb in participants treated with PF-06647020.

    Time frame: Prior to the start of treatment on Day 1 of Cycle 1 up to end of treatment (approximately 31 months).

  25. Percentage of Participants With Objective Response - Q3W Regimen

    Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).

  26. Duration of Response - Q3W Regimen

    Duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

    Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).

  27. Disease Control Rate - Q3W Regimen

    The disease control rate (DCR) was defined as the percentage of participants with a confirmed CR, PR, non-CR/non-PD or stable disease (SD) according to the appropriate analysis set. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).

  28. Time to Progression - Q3W Regimen

    Time to progression (TTP) was the time from start date to the date of the first documentation of PD. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

    Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).

  29. Progression Free Survival - Q3W Regimen

    Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

    Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).

  30. Dose Normalized AUCinf [AUCinf(dn)] for PF-06647020 [DDI Sub-Study]

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  31. Dose Normalized AUClast [AUClast(dn)] for PF-06647020 [DDI Sub-Study]

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  32. Dose Normalized AUCtau [AUCtau(dn)] for PF-06647020 [DDI Sub-Study]

    AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  33. Dose Normalized Cmax [Cmax(dn)] for PF-06647020 [DDI Sub-Study]

    Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  34. AUCinf(dn) for PF-06380101 [DDI Sub-Study]

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  35. AUClast(dn) for PF-06380101 [DDI Sub-Study]

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  36. AUCtau(dn) for PF-06380101 [DDI Sub-Study]

    AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  37. Cmax(dn) for PF-06380101 [DDI Sub-Study]

    Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  38. AUCinf(dn) for hu6M024 mAb [DDI Sub-Study]

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  39. AUClast(dn) for hu6M024 mAb [DDI Sub-Study]

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  40. AUCtau(dn) for hu6M024 mAb [DDI Sub-Study]

    AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  41. Cmax(dn) for hu6M024 mAb [DDI Sub-Study]

    Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.

    Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).

  42. AUCtau for PF-06647020 - Q2W Regimen

    Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06647020 was determined using linear/log trapezoidal method.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  43. Cmax for PF-06647020 -Q2W Regimen

    Cmax is maximum observed serum concentration. Cmax for PF-06647020 was observed directly from data.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  44. Vss for PF-06647020 - Q2W Regimen

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  45. CL for PF-06647020 - Q2W Regimen

    Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance for PF-06647020 was calculated as dose/AUCinf for single dose and dose/AUCtau for multiple dose, where AUCinf was the area under the serum concentration-time profile from time 0 extrapolated to infinite time and AUCtau was the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing).

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  46. t1/2 for PF-06647020 - Q2W Regimen

    Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  47. Rac for PF-06647020 - Q2W Regimen

    Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

    Time frame: pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).

  48. Tmax for PF-06647020 - Q2W Regimen

    Tmax is the time for Cmax. Tmax for PF-06647020 was observed directly from data as time of first occurrence.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  49. AUClast for PF-06647020 - Q2W Regimen

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06647020 was determined using linear/log trapezoidal method.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  50. AUCinf for PF-06647020 - Q2W Regimen

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  51. AUCtau for PF-06380101 - Q2W Regimen

    Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06380101 was determined using linear/log trapezoidal method.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  52. Cmax for PF-06380101 - Q2W Regimen

    Cmax is maximum observed serum concentration. Cmax for PF-06380101 was observed directly from data.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  53. t1/2 for PF-06380101 - Q2W Regimen

    Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  54. Rac for PF-06380101 - Q2W Regimen

    Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

    Time frame: pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).

  55. Tmax for PF-06380101 - Q2W Regimen

    Tmax is the time for Cmax. Tmax for PF-06380101 was observed directly from data as time of first occurrence.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  56. AUClast for PF-06380101- Q2W Regimen

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06380101 was determined using linear/log trapezoidal method.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  57. AUCinf for PF-06380101- Q2W Regimen

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  58. AUCtau for hu6M024 mAb- Q2W Regimen

    Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for hu6M024 mA was determined using linear/log trapezoidal method.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  59. Cmax for hu6M024 mAb -Q2W Regimen

    Cmax is maximum observed serum concentration. Cmax for hu6M024 mAb was observed directly from data.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  60. t1/2 for hu6M024 mAb - Q2W Regimen

    Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  61. Rac for hu6M024 mAb - Q2W Regimen

    Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

    Time frame: pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).

  62. Tmax for hu6M024 mAb - Q2W Regimen

    Tmax is the time for Cmax. Tmax for hu6M024 mAb was observed directly from data as time of first occurrence.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  63. AUClast for hu6M024 mAb - Q2W Regimen

    AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for hu6M024 mAb was determined using linear/log trapezoidal method.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  64. AUCinf for hu6M024 mAb - Q2W Regimen

    AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).

  65. Number of Participants With ADA and NAb of PF-06647020 - Q2W Regimen

    To evaluate the immunogenicity as measured by presence of ADA and NAb in participants treated with PF-06647020.

    Time frame: 2 hours before the first dose up to 30 days after the last dose (approximately 18 months).

  66. Percentage of Participants With Objective Response - Q2W Regimen

    Percentage of participants with objective response based on assessment of CR or PR according to RECIST version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).

  67. Duration of Response - Q2W Regimen

    For participants with an objective response, duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of PD or death due to any cause. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

    Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).

  68. Disease Control Rate - Q2W Regimen

    The disease control rate (DCR) was defined as the percentage of participants with a confirmed CR, PR or SD according to the appropriate analysis set. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).

  69. Time to Progression - Q2W Regimen

    Time to progression (TTP) was the time from start date to the date of the first documentation of PD. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

    Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).

  70. Progression Free Survival - Q2W Regimen

    Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

    Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).

07

Results

Posted Dec 17, 2020

Participant flow

Participant flow — Overall Study
MilestonePF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Started222596631012
Received treatment222496631012
Completed1212583166
Not completed1013383246
Withdrew: Death0000130002
Withdrew: Lost to follow-up001091000
Withdrew: Other0002102241
Withdrew: Participant refused further follow-up100160003

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen

A DLT was any of the following adverse events(AEs) in the first cycle of treatment (within 21 days of first dose or until participant received second infusion if there were treatment delays). (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 anemia; Grade \>=3 thrombocytopenia with clinically significant bleeding. (2) Hepatic, including Grade \>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>=3.0 x upper limit of normal (ULN) concurrent with elevation in bilirubin \>=2.0 x ULN; (3) Grade \>=3 non-hematologic, non-hepatic major organ toxicities; delayed by \>2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. A participant was on study for at least 21 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 21 days.

Time frame:
First Cycle, Day 1 up to Day 21
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen000002
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) - Q3W Regimen (All-Causality)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.

Time frame:
From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) - Q3W Regimen (All-Causality)
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
AEs2224966
SAEs0001332
PrimaryNumber of Participants With Treatment-Emergent AEs - Q3W Regimen (Treatment-Related)

A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.

Time frame:
From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent AEs - Q3W Regimen (Treatment-Related)
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
AEs1114845
SAEs000190
PrimaryNumber of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q3W Regimen (All-Causality and Treatment-Related)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication. All AEs were graded by the investigator according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.

Time frame:
From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q3W Regimen (All-Causality and Treatment-Related)
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Grade 1 (all-causality)001160
Grade 2 (all-causality)1202181
Grade 3 (all-causality)1011495
Grade 4 (all-causality)0000140
Grade 5 (all-causality)000090
Missing or Unknown (all-causality)000000
Grade 1 (treatment-related)0111231
Grade 2 (treatment-related)0003211
Grade 3 (treatment-related)1000283
Grade 4 (treatment-related)0000120
Grade 5 (treatment-related)000000
Missing or Unknown (treatment-related)000000
PrimaryNumber of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q3W Regimen

Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: absolute neutrophils, lymphopenia, white blood cell, anemia, platelets.

Time frame:
From baseline to end of treatment (approximately 32 months).
Reported as:
Count of participants · Participants
Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q3W Regimen
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Absolute neutrophils0001282
Lymphopenia1100212
White blood cells0000181
Anemia000020
Platelets000020
PrimaryNumber of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q3W Regimen

Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: hypokalemia, hypophosphatemia, aspartate aminotransferase, hyperglycemia, alkaline phosphatase, hyponatremia, alanine aminotransferase, hypoalbuminemia, total bilirubin, hypercalcemia, hypomagnesemia , creatinine, gamma glutamyl transferase, hypocalcemia.

Time frame:
From baseline to end of treatment (approximately 32 months).
Reported as:
Count of participants · Participants
Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q3W Regimen
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Hypokalemia000081
Hypophosphatemia000081
Aspartate aminotransferase000060
Hyperglycemia000060
Alkaline phosphatase000060
Hyponatremia100040
Alanine aminotransferase000040
Hypoalbuminemia000030
Total bilirubin000020
Hypercalcemia000020
Hypomagnesemia000020
Creatinine000010
Gamma glutamyl transferase000010
Hypocalcemia000010
PrimaryNumber of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q3W Regimen

Participants who experienced urinalysis laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with urinalysis laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above.

Time frame:
From baseline to end of treatment (approximately 32 months).
Reported as:
Count of participants · Participants
Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q3W Regimen
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q3W Regimen000000
PrimaryNumber of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q3W Regimen

Participants who experienced coagulation laboratory test abnormalities were summarized according to worst toxicity grade observed for each coagulation laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with coagulation laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameter: partial thromboplastin time.

Time frame:
From baseline to end of treatment (approximately 32 months).
Reported as:
Count of participants · Participants
Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q3W Regimen
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q3W Regimen000010
PrimaryNumber of Participants With DLTs - Q2W Regimen

A DLT was any of the following AEs in the first cycle of treatment (within 28 days of first dose or until participant received second infusion if there were treatment delayed) in the single agent dose escalation. (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 thrombocytopenia; treatment delay \>14 days because of hematologic AE; (2) Hepatic: including Grade\>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; ALT or AST\>=3.0 x ULN concurrent with elevation in bilirubin\>=2.0 x ULN; (3) Grade \>=3 non-hematologic, non-hepatic major organ toxicities; delayed by \>2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. Grade \>=3 headache lasting \>48 hours in presence of supportive care. A participant was on study for at least 28 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 28 days.

Time frame:
First cycle, Day 1 up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With DLTs - Q2W Regimen
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Number of Participants With DLTs - Q2W Regimen012
PrimaryNumber of Participants With Treatment-Emergent AEs - Q2W Regimen (All-Causality)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.

Time frame:
From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent AEs - Q2W Regimen (All-Causality)
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
AEs31012
SAEs147
PrimaryNumber of Participants With Treatment-Emergent AEs - Q2W Regimen (Treatment-Related)

A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.

Time frame:
From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent AEs - Q2W Regimen (Treatment-Related)
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
AEs31012
SAEs022
PrimaryNumber of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q2W Regimen (All-Causality and Treatment-Related)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication. All AEs were graded by the investigator according to the NCI CTCAE version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.

Time frame:
From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q2W Regimen (All-Causality and Treatment-Related)
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Grade 1 (all-causality)000
Grade 2 (all-causality)232
Grade 3 (all-causality)157
Grade 4 (all-causality)022
Grade 5 (all-causality)001
Missing or Unknown (all-causality)000
Grade 1 (treatment-related)000
Grade 2 (treatment-related)345
Grade 3 (treatment-related)046
Grade 4 (treatment-related)021
Grade 5 (treatment-related)000
Missing or Unknown (treatment-related)000
PrimaryNumber of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q2W Regimen

Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: absolute neutrophils, lymphopenia, white blood cell, anemia.

Time frame:
From baseline to end of treatment (approximately 19 months).
Reported as:
Count of participants · Participants
Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q2W Regimen
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Absolute neutrophils035
Lymphopenia004
White blood cells022
Anemia001
PrimaryNumber of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q2W Regimen

Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: hypokalemia, hyponatremia, hypomagnesemia, hypoalbuminemia, hypocalcemia, hypophosphatemia, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase.

Time frame:
From baseline to end of treatment (approximately 19 months).
Reported as:
Count of participants · Participants
Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q2W Regimen
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Hypokalemia012
Hyponatremia012
Hypomagnesemia002
Hypoalbuminemia011
Hypocalcemia101
Hypophosphatemia010
Alanine aminotransferase001
Aspartate aminotransferase001
Alkaline phosphatase001
PrimaryNumber of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q2W Regimen

Participants who experienced urinalysis laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with urinalysis laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above.

Time frame:
Baseline and Day 1 of Cycle 1
Reported as:
Count of participants · Participants
Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q2W Regimen
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q2W Regimen000
PrimaryNumber of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q2W Regimen

Participants who experienced coagulation laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with coagulation laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameter: prothrombin time international normalized ratio.

Time frame:
From baseline to end of treatment (approximately 19 months).
Reported as:
Count of participants · Participants
Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q2W Regimen
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q2W Regimen001
SecondaryArea Under the Concentration-Time Profile From Time 0 to Time Tau (AUCtau) for PF-06647020 - Q3W Regimen

Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06647020 was determined using linear/log trapezoidal method.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · microgram•hour/milliliter (µg•hr/mL)
Area Under the Concentration-Time Profile From Time 0 to Time Tau (AUCtau) for PF-06647020 - Q3W Regimen
microgram•hour/milliliter (µg•hr/mL)PF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA4570 ± 304782 ± 616929 ± 80
Cycle 4, Multiple DoseNA ± NA—NA ± NA4201 ± 955834 ± 60NA ± NA
SecondaryMaximum Observed Serum Concentration (Cmax) for PF-06647020 -Q3W Regimen

Cmax is maximum observed serum concentration. Cmax for PF-06647020 was observed directly from data.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · microgram/milliliter (µg/mL)
Maximum Observed Serum Concentration (Cmax) for PF-06647020 -Q3W Regimen
microgram/milliliter (µg/mL)PF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA65.77 ± 2579.77 ± 4596.11 ± 47
Cycle 4, Multiple DoseNA ± NA—NA ± NA55.41 ± 5392.94 ± 50NA ± NA
SecondaryClearance (CL) for PF-06647020 - Q3W Regimen

Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance for PF-06647020 was calculated as dose/AUCinf for single dose and dose/AUCtau for multiple dose, where AUCinf was the area under the serum concentration-time profile from time 0 extrapolated to infinite time and AUCtau was the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing).

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · Liter/hour (L/hr)
Clearance (CL) for PF-06647020 - Q3W Regimen
Liter/hour (L/hr)PF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA0.03464 ± 270.03956 ± 600.03694 ± 72
Cycle 4, Multiple DoseNA ± NA—NA ± NA0.03640 ± 420.03121 ± 60NA ± NA
SecondaryVolume of Distribution at Steady State (Vss) for PF-06647020 - Q3W Regimen

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · Liter (L)
Volume of Distribution at Steady State (Vss) for PF-06647020 - Q3W Regimen
Liter (L)PF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA3.498 ± 263.199 ± 403.947 ± 52
Cycle 4, Multiple DoseNA ± NA—NA ± NA3.230 ± 462.808 ± 47NA ± NA
SecondaryTerminal Half-Life (t1/2) for PF-06647020 - Q3W Regimen

Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Mean · day
Terminal Half-Life (t1/2) for PF-06647020 - Q3W Regimen
dayPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA3.600 ± 0.4873.107 ± 1.1613.514 ± 0.696
Cycle 4, Multiple DoseNA ± NA—NA ± NA4.013 ± 2.8914.007 ± 1.496NA ± NA
SecondaryObserved Accumulation Ratio (Rac) for PF-06647020 - Q3W Regimen

Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

Time frame:
pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).
Reported as:
Geometric mean · Ratio
Observed Accumulation Ratio (Rac) for PF-06647020 - Q3W Regimen
RatioPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Observed Accumulation Ratio (Rac) for PF-06647020 - Q3W RegimenNA ± NA—NA ± NA1.046 ± 611.094 ± 39NA ± NA
SecondaryTime for Cmax (Tmax) for PF-06647020 - Q3W Regimen

Tmax is the time for Cmax. Tmax for PF-06647020 was observed directly from data as time of first occurrence.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Median · hour
Time for Cmax (Tmax) for PF-06647020 - Q3W Regimen
hourPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA (NA to NA)NA (NA to NA)NA (NA to NA)2.48 (0.950 to 4.17)1.08 (0.950 to 70.3)2.49 (0.983 to 24.1)
Cycle 4, Multiple DoseNA (NA to NA)—NA (NA to NA)3.05 (0.967 to 24.0)1.65 (0.917 to 48.2)NA (NA to NA)
SecondaryArea Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for PF-06647020 - Q3W Regimen

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06647020 was determined using linear/log trapezoidal method.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL
Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for PF-06647020 - Q3W Regimen
µg•hr/mLPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA4570 ± 304674 ± 634450 ± 198
Cycle 4, Multiple DoseNA ± NA—NA ± NA4157 ± 985428 ± 83NA ± NA
SecondaryArea Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06647020 - Q3W Regimen

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for PF-06647020 was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL
Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06647020 - Q3W Regimen
µg•hr/mLPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA4637 ± 304829 ± 637052 ± 81
Cycle 4, Multiple DoseNA ± NA—NA ± NA4312 ± 1026086 ± 62NA ± NA
SecondaryAUCtau for PF-06380101 - Q3W Regimen

Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06380101 was determined using linear/log trapezoidal method.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · nanogram•hour/milliliter (ng•hr/mL)
AUCtau for PF-06380101 - Q3W Regimen
nanogram•hour/milliliter (ng•hr/mL)PF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA844.6 ± 46803.9 ± 681022 ± 78
Cycle 4, Multiple DoseNA ± NA—NA ± NA418.3 ± 106647.9 ± 46NA ± NA
SecondaryCmax for PF-06380101 - Q3W Regimen

Cmax is maximum observed serum concentration. Cmax for PF-06380101 was observed directly from data.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Cmax for PF-06380101 - Q3W Regimen
nanogram/milliliter (ng/mL)PF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA7.156 ± 396.934 ± 697.660 ± 47
Cycle 4, Multiple DoseNA ± NA—NA ± NA3.379 ± 845.746 ± 60NA ± NA
Secondaryt1/2 for PF-06380101 - Q3W Regimen

Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Mean · day
t1/2 for PF-06380101 - Q3W Regimen
dayPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA3.150 ± 0.4262.881 ± 0.6043.210 ± 0.473
Cycle 4, Multiple DoseNA ± NA—NA ± NA2.827 ± 0.3912.781 ± 0.676NA ± NA
SecondaryRac for PF-06380101 - Q3W Regimen

Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

Time frame:
pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).
Reported as:
Geometric mean · Ratio
Rac for PF-06380101 - Q3W Regimen
RatioPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Rac for PF-06380101 - Q3W RegimenNA ± NA—NA ± NA0.5454 ± 400.8916 ± 41NA ± NA
SecondaryTmax for PF-06380101 - Q3W Regimen

Tmax is the time for Cmax. Tmax for PF-06380101 was observed directly from data as time of first occurrence.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Median · hour
Tmax for PF-06380101 - Q3W Regimen
hourPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA (NA to NA)NA (NA to NA)NA (NA to NA)23.6 (4.00 to 48.0)23.9 (3.90 to 141)23.4 (4.00 to 74.0)
Cycle 4, Multiple DoseNA (NA to NA)—NA (NA to NA)23.8 (23.6 to 24.0)21.9 (3.67 to 96.0)NA (NA to NA)
SecondaryAUClast for PF-06380101 - Q3W Regimen

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06380101 was determined using linear/log trapezoidal method.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · ng•hr/mL
AUClast for PF-06380101 - Q3W Regimen
ng•hr/mLPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA844.6 ± 46799.3 ± 68490.5 ± 615
Cycle 4, Multiple DoseNA ± NA—NA ± NA418.5 ± 106643.6 ± 48NA ± NA
SecondaryAUCinf for PF-06380101 - Q3W Regimen

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for PF-06380101 was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · ng•hr/mL
AUCinf for PF-06380101 - Q3W Regimen
ng•hr/mLPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA851.4 ± 45812.2 ± 681020 ± 95
Cycle 4, Multiple DoseNA ± NA—NA ± NA422.9 ± 105645.2 ± 48NA ± NA
SecondaryAUCtau for hu6M024 mAb - Q3W Regimen

Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for hu6M024 mAb was determined using linear/log trapezoidal method.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUCtau for hu6M024 mAb - Q3W Regimen
µg•hr/mLPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA6968 ± 325562 ± 628451 ± 78
Cycle 4, Multiple DoseNA ± NA—NA ± NA6122 ± 1456210 ± 80NA ± NA
SecondaryCmax for hu6M024 mAb - Q3W Regimen

Cmax is maximum observed serum concentration. Cmax for hu6M024 mAb was observed directly from data.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · µg/mL
Cmax for hu6M024 mAb - Q3W Regimen
µg/mLPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA83.33 ± 2084.83 ± 4399.37 ± 47
Cycle 4, Multiple DoseNA ± NA—NA ± NA77.76 ± 7682.33 ± 40NA ± NA
Secondaryt1/2 for hu6M024 mAb - Q3W Regimen

Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Mean · day
t1/2 for hu6M024 mAb - Q3W Regimen
dayPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA4.505 ± 0.6503.674 ± 1.5124.386 ± 0.895
Cycle 4, Multiple Dose——NA ± NA5.087 ± 2.6265.232 ± 2.259NA ± NA
SecondaryRac for hu6M024 mAb - Q3W Regimen

Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

Time frame:
pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).
Reported as:
Geometric mean · Ratio
Rac for hu6M024 mAb - Q3W Regimen
RatioPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Rac for hu6M024 mAb - Q3W RegimenNA ± NA—NA ± NA1.022 ± 1080.9865 ± 48NA ± NA
SecondaryTmax for hu6M024 mAb - Q3W Regimen

Tmax is the time for Cmax. Tmax for hu6M024 mAb was observed directly from data as time of first occurrence.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Median · hour
Tmax for hu6M024 mAb - Q3W Regimen
hourPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA (NA to NA)NA (NA to NA)NA (NA to NA)4.00 (0.950 to 4.17)3.70 (0.933 to 24.1)2.31 (0.983 to 4.00)
Cycle 4, Multiple DoseNA (NA to NA)—NA (NA to NA)3.05 (1.00 to 23.6)3.90 (1.00 to 41.8)NA (NA to NA)
SecondaryAUClast for hu6M024 mAb - Q3W Regimen

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for hu6M024 mAb was determined using linear/log trapezoidal method.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUClast for hu6M024 mAb - Q3W Regimen
µg•hr/mLPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA6969 ± 325449 ± 645247 ± 221
Cycle 4, Multiple DoseNA ± NA—NA ± NA6127 ± 1475885 ± 97NA ± NA
SecondaryAUCinf for hu6M024 mAb - Q3W Regimen

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for hu6M024 mAb was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUCinf for hu6M024 mAb - Q3W Regimen
µg•hr/mLPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Cycle 1, Single DoseNA ± NANA ± NANA ± NA7189 ± 325608 ± 658760 ± 80
Cycle 4, Multiple Dose——NA ± NA6517 ± 1566191 ± 94NA ± NA
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibody (NAb) of PF-06647020 - Q3W Regimen

To evaluate the immunogenicity as measured by presence of ADA and NAb in participants treated with PF-06647020.

Time frame:
Prior to the start of treatment on Day 1 of Cycle 1 up to end of treatment (approximately 31 months).
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibody (NAb) of PF-06647020 - Q3W Regimen
ParticipantsPF-06647020 0.2 mg/kg(Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)
Overall incidence of ADA1000100
Overall incidence of NAb100090
SecondaryPercentage of Participants With Objective Response - Q3W Regimen

Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response - Q3W Regimen
Percentage of participantsNSCLC - Q3W RegimenOVCA - Q3W RegimenTNBC - Q3W Regimen
Percentage of Participants With Objective Response - Q3W Regimen16.0 (4.5 to 36.1)27.3 (15.0 to 42.8)20.7 (8.0 to 39.7)
SecondaryDuration of Response - Q3W Regimen

Duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

Time frame:
Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Reported as:
Median · month
Duration of Response - Q3W Regimen
monthNSCLC - Q3W RegimenOVCA - Q3W RegimenTNBC - Q3W Regimen
Duration of Response - Q3W Regimen5.7 (1.5 to 9.9)4.2 (2.8 to 8.3)4.3 (1.3 to 10.2)
SecondaryDisease Control Rate - Q3W Regimen

The disease control rate (DCR) was defined as the percentage of participants with a confirmed CR, PR, non-CR/non-PD or stable disease (SD) according to the appropriate analysis set. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Reported as:
Number · Percentage of participants
Disease Control Rate - Q3W Regimen
Percentage of participantsNSCLC - Q3W RegimenOVCA - Q3W RegimenTNBC - Q3W Regimen
Disease Control Rate - Q3W Regimen56.0 (34.93 to 75.60)72.7 (57.21 to 85.04)48.3 (29.45 to 67.47)
SecondaryTime to Progression - Q3W Regimen

Time to progression (TTP) was the time from start date to the date of the first documentation of PD. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

Time frame:
Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Reported as:
Median · month
Time to Progression - Q3W Regimen
monthNSCLC - Q3W RegimenOVCA - Q3W RegimenTNBC - Q3W Regimen
Time to Progression - Q3W Regimen2.9 (1.4 to 6.1)3.1 (2.3 to 5.5)2.2 (1.4 to 5.5)
SecondaryProgression Free Survival - Q3W Regimen

Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

Time frame:
Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Reported as:
Median · month
Progression Free Survival - Q3W Regimen
monthNSCLC - Q3W RegimenOVCA - Q3W RegimenTNBC - Q3W Regimen
Progression Free Survival - Q3W Regimen2.9 (1.4 to 6.1)2.9 (2.3 to 5.5)1.5 (1.4 to 4.3)
SecondaryDose Normalized AUCinf [AUCinf(dn)] for PF-06647020 [DDI Sub-Study]

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL/mg
Dose Normalized AUCinf [AUCinf(dn)] for PF-06647020 [DDI Sub-Study]
µg•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
Dose Normalized AUCinf [AUCinf(dn)] for PF-06647020 [DDI Sub-Study]29.56 ± 4623.47 ± 53
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.3105 · Geometric mean ratio (gmr): 79.38 · 90% CI 54.01 to 116.65
SecondaryDose Normalized AUClast [AUClast(dn)] for PF-06647020 [DDI Sub-Study]

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL/mg
Dose Normalized AUClast [AUClast(dn)] for PF-06647020 [DDI Sub-Study]
µg•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
Dose Normalized AUClast [AUClast(dn)] for PF-06647020 [DDI Sub-Study]31.51 ± 5124.34 ± 50
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.2316 · Geometric mean ratio (gmr): 77.23 · 90% CI 53.80 to 110.87
SecondaryDose Normalized AUCtau [AUCtau(dn)] for PF-06647020 [DDI Sub-Study]

AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL/mg
Dose Normalized AUCtau [AUCtau(dn)] for PF-06647020 [DDI Sub-Study]
µg•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
Dose Normalized AUCtau [AUCtau(dn)] for PF-06647020 [DDI Sub-Study]29.25 ± 4624.85 ± 48
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.4264 · Geometric mean ratio (gmr): 84.97 · 90% CI 60.05 to 120.22
SecondaryDose Normalized Cmax [Cmax(dn)] for PF-06647020 [DDI Sub-Study]

Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · µg/mL/mg
Dose Normalized Cmax [Cmax(dn)] for PF-06647020 [DDI Sub-Study]
µg/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
Dose Normalized Cmax [Cmax(dn)] for PF-06647020 [DDI Sub-Study]0.5010 ± 490.4425 ± 39
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.5123 · Geometric mean ratio (gmr): 88.32 · 90% CI 64.03 to 121.82
SecondaryAUCinf(dn) for PF-06380101 [DDI Sub-Study]

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · ng•hr/mL/mg
AUCinf(dn) for PF-06380101 [DDI Sub-Study]
ng•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
AUCinf(dn) for PF-06380101 [DDI Sub-Study]5.787 ± 1165.275 ± 123
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.8240 · Geometric mean ratio (gmr): 91.15 · 90% CI 44.79 to 185.50
SecondaryAUClast(dn) for PF-06380101 [DDI Sub-Study]

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · ng•hr/mL/mg
AUClast(dn) for PF-06380101 [DDI Sub-Study]
ng•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
AUClast(dn) for PF-06380101 [DDI Sub-Study]5.681 ± 1125.089 ± 128
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.7922 · Geometric mean ratio (gmr): 89.58 · 90% CI 43.94 to 182.62
SecondaryAUCtau(dn) for PF-06380101 [DDI Sub-Study]

AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · ng•hr/mL/mg
AUCtau(dn) for PF-06380101 [DDI Sub-Study]
ng•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
AUCtau(dn) for PF-06380101 [DDI Sub-Study]5.746 ± 1155.239 ± 123
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.8240 · Geometric mean ratio (gmr): 91.17 · 90% CI 44.87 to 185.25
SecondaryCmax(dn) for PF-06380101 [DDI Sub-Study]

Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · ng/mL/mg
Cmax(dn) for PF-06380101 [DDI Sub-Study]
ng/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
Cmax(dn) for PF-06380101 [DDI Sub-Study]0.04336 ± 1130.04436 ± 118
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.9553 · Geometric mean ratio (gmr): 102.31 · 90% CI 51.08 to 204.90
SecondaryAUCinf(dn) for hu6M024 mAb [DDI Sub-Study]

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL/mg
AUCinf(dn) for hu6M024 mAb [DDI Sub-Study]
µg•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
AUCinf(dn) for hu6M024 mAb [DDI Sub-Study]31.94 ± 4525.92 ± 46
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.2951 · Geometric mean ratio (gmr): 81.14 · 90% CI 57.99 to 113.54
SecondaryAUClast(dn) for hu6M024 mAb [DDI Sub-Study]

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL/mg
AUClast(dn) for hu6M024 mAb [DDI Sub-Study]
µg•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
AUClast(dn) for hu6M024 mAb [DDI Sub-Study]31.30 ± 4426.30 ± 48
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.3769 · Geometric mean ratio (gmr): 84.02 · 90% CI 60.24 to 117.19
SecondaryAUCtau(dn) for hu6M024 mAb [DDI Sub-Study]

AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · µg•hr/mL/mg
AUCtau(dn) for hu6M024 mAb [DDI Sub-Study]
µg•hr/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
AUCtau(dn) for hu6M024 mAb [DDI Sub-Study]31.29 ± 4426.96 ± 46
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.4385 · Geometric mean ratio (gmr): 86.15 · 90% CI 62.20 to 119.32
SecondaryCmax(dn) for hu6M024 mAb [DDI Sub-Study]

Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.

Time frame:
pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Reported as:
Geometric mean · µg/mL/mg
Cmax(dn) for hu6M024 mAb [DDI Sub-Study]
µg/mL/mgPF-06647020 2.8 mg/kg (Q3W-DDI)PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI)
Cmax(dn) for hu6M024 mAb [DDI Sub-Study]0.4378 ± 590.3885 ± 37
Statistical analysis
  • PF-06647020 2.8 mg/kg (Q3W-DDI) vs PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) · ANOVA · p = 0.5678 · Geometric mean ratio (gmr): 88.75 · 90% CI 62.24 to 126.56
SecondaryAUCtau for PF-06647020 - Q2W Regimen

Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06647020 was determined using linear/log trapezoidal method.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUCtau for PF-06647020 - Q2W Regimen
µg•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose3627 ± 626541 ± 386319 ± 45
Cycle 3, Multiple DoseNA ± NA9858 ± 216933 ± 43
SecondaryCmax for PF-06647020 -Q2W Regimen

Cmax is maximum observed serum concentration. Cmax for PF-06647020 was observed directly from data.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · µg/mL
Cmax for PF-06647020 -Q2W Regimen
µg/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose97.79 ± 1499.69 ± 3290.28 ± 32
Cycle 3, Multiple DoseNA ± NA114.7 ± 2681.91 ± 34
SecondaryVss for PF-06647020 - Q2W Regimen

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · Liter
Vss for PF-06647020 - Q2W Regimen
LiterPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single DoseNA ± NA2.566 ± 442.953 ± 36
Cycle 3, Multiple DoseNA ± NA2.349 ± 243.106 ± 32
SecondaryCL for PF-06647020 - Q2W Regimen

Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance for PF-06647020 was calculated as dose/AUCinf for single dose and dose/AUCtau for multiple dose, where AUCinf was the area under the serum concentration-time profile from time 0 extrapolated to infinite time and AUCtau was the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing).

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · L/hr
CL for PF-06647020 - Q2W Regimen
L/hrPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single DoseNA ± NA0.03075 ± 490.03238 ± 39
Cycle 3, Multiple DoseNA ± NA0.02044 ± 250.02688 ± 35
Secondaryt1/2 for PF-06647020 - Q2W Regimen

Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Mean · day
t1/2 for PF-06647020 - Q2W Regimen
dayPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single DoseNA ± NA2.700 ± 0.6252.874 ± 0.385
Cycle 3, Multiple DoseNA ± NA3.633 ± 0.4153.600 ± 0.583
SecondaryRac for PF-06647020 - Q2W Regimen

Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

Time frame:
pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).
Reported as:
Geometric mean · Ratio
Rac for PF-06647020 - Q2W Regimen
RatioPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Rac for PF-06647020 - Q2W RegimenNA ± NA1.425 ± 351.211 ± 18
SecondaryTmax for PF-06647020 - Q2W Regimen

Tmax is the time for Cmax. Tmax for PF-06647020 was observed directly from data as time of first occurrence.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Median · hour
Tmax for PF-06647020 - Q2W Regimen
hourPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose3.98 (0.983 to 4.02)2.45 (0.983 to 23.7)1.05 (0.900 to 4.00)
Cycle 3, Multiple DoseNA (NA to NA)1.07 (0.983 to 23.9)2.36 (0.983 to 4.03)
SecondaryAUClast for PF-06647020 - Q2W Regimen

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06647020 was determined using linear/log trapezoidal method.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUClast for PF-06647020 - Q2W Regimen
µg•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose3641 ± 626490 ± 396342 ± 46
Cycle 3, Multiple DoseNA ± NA9864 ± 207000 ± 43
SecondaryAUCinf for PF-06647020 - Q2W Regimen

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUCinf for PF-06647020 - Q2W Regimen
µg•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single DoseNA ± NA6798 ± 416535 ± 46
Cycle 3, Multiple DoseNA ± NA10570 ± 227445 ± 44
SecondaryAUCtau for PF-06380101 - Q2W Regimen

Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06380101 was determined using linear/log trapezoidal method.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · ng•hr/mL
AUCtau for PF-06380101 - Q2W Regimen
ng•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose568.9 ± 12860.3 ± 52740.5 ± 62
Cycle 3, Multiple DoseNA ± NA731.5 ± 61589.8 ± 33
SecondaryCmax for PF-06380101 - Q2W Regimen

Cmax is maximum observed serum concentration. Cmax for PF-06380101 was observed directly from data.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · ng/mL
Cmax for PF-06380101 - Q2W Regimen
ng/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose6.084 ± 596.665 ± 495.779 ± 59
Cycle 3, Multiple DoseNA ± NA4.857 ± 664.248 ± 34
Secondaryt1/2 for PF-06380101 - Q2W Regimen

Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Mean · day
t1/2 for PF-06380101 - Q2W Regimen
dayPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose2.507 ± 0.4112.646 ± 0.4532.592 ± 0.331
Cycle 3, Multiple DoseNA ± NA2.755 ± 0.6533.007 ± 0.373
SecondaryRac for PF-06380101 - Q2W Regimen

Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

Time frame:
pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).
Reported as:
Geometric mean · Ratio
Rac for PF-06380101 - Q2W Regimen
RatioPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Rac for PF-06380101 - Q2W RegimenNA ± NA0.9980 ± 260.9657 ± 25
SecondaryTmax for PF-06380101 - Q2W Regimen

Tmax is the time for Cmax. Tmax for PF-06380101 was observed directly from data as time of first occurrence.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Median · hour
Tmax for PF-06380101 - Q2W Regimen
hourPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose3.98 (3.98 to 4.02)4.05 (3.75 to 72.1)24.7 (3.72 to 48.5)
Cycle 3, Multiple DoseNA (NA to NA)71.7 (3.75 to 166)22.8 (3.75 to 48.3)
SecondaryAUClast for PF-06380101- Q2W Regimen

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06380101 was determined using linear/log trapezoidal method.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · ng•hr/mL
AUClast for PF-06380101- Q2W Regimen
ng•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose569.9 ± 12866.0 ± 53743.5 ± 63
Cycle 3, Multiple DoseNA ± NA728.9 ± 60593.3 ± 33
SecondaryAUCinf for PF-06380101- Q2W Regimen

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · ng•hr/mL
AUCinf for PF-06380101- Q2W Regimen
ng•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose584.4 ± 11888.5 ± 54763.2 ± 62
Cycle 3, Multiple DoseNA ± NA738.8 ± 69617.9 ± 32
SecondaryAUCtau for hu6M024 mAb- Q2W Regimen

Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for hu6M024 mA was determined using linear/log trapezoidal method.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUCtau for hu6M024 mAb- Q2W Regimen
µg•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose4089 ± 527325 ± 476911 ± 44
Cycle 3, Multiple DoseNA ± NA10440 ± 258432 ± 42
SecondaryCmax for hu6M024 mAb -Q2W Regimen

Cmax is maximum observed serum concentration. Cmax for hu6M024 mAb was observed directly from data.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · µg/mL
Cmax for hu6M024 mAb -Q2W Regimen
µg/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose72.04 ± 23102.1 ± 3886.26 ± 27
Cycle 3, Multiple DoseNA ± NA106.6 ± 3789.66 ± 33
Secondaryt1/2 for hu6M024 mAb - Q2W Regimen

Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Mean · day
t1/2 for hu6M024 mAb - Q2W Regimen
dayPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single DoseNA ± NA3.436 ± 0.7503.645 ± 0.752
Cycle 3, Multiple DoseNA ± NA4.734 ± 0.6704.124 ± 1.218
SecondaryRac for hu6M024 mAb - Q2W Regimen

Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).

Time frame:
pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).
Reported as:
Geometric mean · Ratio
Rac for hu6M024 mAb - Q2W Regimen
RatioPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Rac for hu6M024 mAb - Q2W RegimenNA ± NA1.280 ± 321.301 ± 35
SecondaryTmax for hu6M024 mAb - Q2W Regimen

Tmax is the time for Cmax. Tmax for hu6M024 mAb was observed directly from data as time of first occurrence.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Median · hour
Tmax for hu6M024 mAb - Q2W Regimen
hourPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose3.98 (1.00 to 4.02)3.87 (0.983 to 4.35)1.05 (0.900 to 23.8)
Cycle 3, Multiple DoseNA (NA to NA)1.05 (0.950 to 3.92)2.36 (0.983 to 24.1)
SecondaryAUClast for hu6M024 mAb - Q2W Regimen

AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for hu6M024 mAb was determined using linear/log trapezoidal method.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUClast for hu6M024 mAb - Q2W Regimen
µg•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single Dose4103 ± 527368 ± 466949 ± 45
Cycle 3, Multiple DoseNA ± NA10460 ± 248555 ± 41
SecondaryAUCinf for hu6M024 mAb - Q2W Regimen

AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Reported as:
Geometric mean · µg•hr/mL
AUCinf for hu6M024 mAb - Q2W Regimen
µg•hr/mLPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Cycle 1, Single DoseNA ± NA7742 ± 477411 ± 48
Cycle 3, Multiple DoseNA ± NA10950 ± 228275 ± 44
SecondaryNumber of Participants With ADA and NAb of PF-06647020 - Q2W Regimen

To evaluate the immunogenicity as measured by presence of ADA and NAb in participants treated with PF-06647020.

Time frame:
2 hours before the first dose up to 30 days after the last dose (approximately 18 months).
Reported as:
Count of participants · Participants
Number of Participants With ADA and NAb of PF-06647020 - Q2W Regimen
ParticipantsPF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
Overall incidence of ADA100
Overall incidence of NAb100
SecondaryPercentage of Participants With Objective Response - Q2W Regimen

Percentage of participants with objective response based on assessment of CR or PR according to RECIST version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response - Q2W Regimen
Percentage of participantsNSCLC - Q2W RegimenOVCA - Q2W Regimen
Percentage of Participants With Objective Response - Q2W Regimen33.3 (4.3 to 77.7)26.3 (9.1 to 51.2)
SecondaryDuration of Response - Q2W Regimen

For participants with an objective response, duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of PD or death due to any cause. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

Time frame:
Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Reported as:
Median · month
Duration of Response - Q2W Regimen
monthNSCLC - Q2W RegimenOVCA - Q2W Regimen
Duration of Response - Q2W RegimenNA (3.7 to NA)6.5 (3.9 to 8.3)
SecondaryDisease Control Rate - Q2W Regimen

The disease control rate (DCR) was defined as the percentage of participants with a confirmed CR, PR or SD according to the appropriate analysis set. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Reported as:
Number · Percentage of participants
Disease Control Rate - Q2W Regimen
Percentage of participantsNSCLC - Q2W RegimenOVCA - Q2W Regimen
Disease Control Rate - Q2W Regimen50 (11.81 to 88.19)84.2 (60.42 to 96.62)
SecondaryTime to Progression - Q2W Regimen

Time to progression (TTP) was the time from start date to the date of the first documentation of PD. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

Time frame:
Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Reported as:
Median · month
Time to Progression - Q2W Regimen
monthNSCLC - Q2W RegimenOVCA - Q2W Regimen
Time to Progression - Q2W Regimen2.7 (1.0 to NA)3.8 (3.1 to 7.4)
SecondaryProgression Free Survival - Q2W Regimen

Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.

Time frame:
Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Reported as:
Median · month
Progression Free Survival - Q2W Regimen
monthNSCLC - Q2W RegimenOVCA - Q2W Regimen
Progression Free Survival - Q2W Regimen2.7 (1.0 to NA)3.8 (3.1 to 7.4)

Adverse events

Collected over From the time the participant took the first dose of study medication through the participant's last visit.(approximately 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06647020 0.2 mg/kg (Q3W Regimen)0/2 (0%)0/2 (0%)2/2 (100%)
PF-06647020 0.5 mg/kg (Q3W Regimen)0/2 (0%)0/2 (0%)2/2 (100%)
PF-06647020 1.25 mg/kg (Q3W Regimen)0/2 (0%)0/2 (0%)2/2 (100%)
PF-06647020 2.1 mg/kg (Q3W Regimen)0/4 (0%)1/4 (25%)4/4 (100%)
PF-06647020 2.8 mg/kg (Q3W Regimen)13/96 (13.5%)33/96 (34.4%)93/96 (96.9%)
PF-06647020 3.7 mg/kg (Q3W Regimen)0/6 (0%)2/6 (33.3%)6/6 (100%)
PF-06647020 2.1 mg/kg (Q2W Regimen)0/3 (0%)1/3 (33.3%)3/3 (100%)
PF-06647020 2.8 mg/kg (Q2W Regimen)0/10 (0%)4/10 (40%)10/10 (100%)
PF-06647020 3.2 mg/kg (Q2W Regimen)2/12 (16.7%)7/12 (58.3%)12/12 (100%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventPF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
DiarrhoeaGastrointestinal disorders0/20/20/20/40/960/61/30/100/12
VomitingGastrointestinal disorders0/20/20/21/42/960/60/31/101/12
HeadacheNervous system disorders0/20/20/21/40/960/60/30/100/12
Abdominal painGastrointestinal disorders0/20/20/20/41/960/60/32/102/12
ConstipationGastrointestinal disorders0/20/20/20/43/961/60/31/100/12
Mental status changesPsychiatric disorders0/20/20/20/41/961/60/30/100/12
AnaemiaBlood and lymphatic system disorders0/20/20/20/41/960/60/31/100/12
NauseaGastrointestinal disorders0/20/20/20/43/960/60/31/101/12
LethargyNervous system disorders0/20/20/20/41/960/60/31/100/12
Pleural effusionRespiratory, thoracic and mediastinal disorders0/20/20/20/43/960/60/31/100/12
Most frequent other events
Showing 10 of 160
Most frequent other events
EventPF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)
FatigueGeneral disorders1/20/22/22/451/963/60/35/107/12
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/22/20/20/45/960/60/30/100/12
AlopeciaSkin and subcutaneous tissue disorders0/20/21/21/441/963/63/38/107/12
NauseaGastrointestinal disorders1/21/21/22/446/964/60/33/107/12
ConstipationGastrointestinal disorders1/20/21/21/433/962/60/36/107/12
HeadacheNervous system disorders0/20/20/22/435/963/60/34/107/12
PalpitationsCardiac disorders0/20/21/20/43/960/60/32/100/12
Pericardial effusionCardiac disorders0/20/21/20/41/960/60/30/100/12
Sinus tachycardiaCardiac disorders0/20/21/20/42/960/60/30/100/12
Abdominal painGastrointestinal disorders0/20/21/20/415/961/60/34/106/12

Baseline characteristics

Baseline analysis population included all enrolled participants who received at least 1 full or partial dose of study medication.

Age, Continuous
Age, Continuous(Years)PF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)Total
Q3W Regimen73.0 ± 2.857.5 ± 14.861.0 ± 2.855.0 ± 13.658.1 ± 11.859.5 ± 8.4———58.4 ± 11.6
Q2W Regimen——————64.0 ± 2.665.5 ± 8.965.6 ± 8.065.4 ± 7.8
Age, Customized
Age, Customized(Participants)PF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)Total
< 18 (Q3W Regimen)0000000000
18-44 (Q3W Regimen)000016000016
45-64 (Q3W Regimen)012349400059
>= 65 (Q3W Regimen)210131200037
< 18 (Q2W Regimen)0000000000
18-44 (Q2W Regimen)0000000000
45-64 (Q2W Regimen)00000015612
>= 65 (Q2W Regimen)00000025613
Sex: Female, Male
Sex: Female, Male(Participants)PF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)Total
Q3W Regimen — Female211380500092
Q3W Regimen — Male011116100020
Q2W Regimen — Female0000003101124
Q2W Regimen — Male0000000011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)Total
Q3W Regimen — American Indian or Alaska Native0000000000
Q3W Regimen — Asian0000100001
Q3W Regimen — Native Hawaiian or Other Pacific Islander0000000000
Q3W Regimen — Black or African American0001500006
Q3W Regimen — White2223886000103
Q3W Regimen — More than one race0000000000
Q3W Regimen — Unknown or Not Reported0000200002
Q2W Regimen — American Indian or Alaska Native0000000000
Q2W Regimen — Asian0000000011
Q2W Regimen — Native Hawaiian or Other Pacific Islander0000000000
Q2W Regimen — Black or African American0000000101
Q2W Regimen — White000000281121
Q2W Regimen — More than one race0000000000
Q2W Regimen — Unknown or Not Reported0000001102
Weight Continuous
Weight Continuous(kilogram (kg))PF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)Total
Q3W Regimen49.2 ± 10.268.8 ± 21.968.7 ± 5.280.7 ± 27.369.9 ± 16.472.2 ± 14.2———70.0 ± 16.6
Q2W Regimen——————68.4 ± 23.878.1 ± 25.568.3 ± 22.572.3 ± 23.4
Body Mass Index (BMI) Continuous
Body Mass Index (BMI) Continuous(kg/m^2)PF-06647020 0.2 mg/kg (Q3W Regimen)PF-06647020 0.5 mg/kg (Q3W Regimen)PF-06647020 1.25 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q3W Regimen)PF-06647020 2.8 mg/kg (Q3W Regimen)PF-06647020 3.7 mg/kg (Q3W Regimen)PF-06647020 2.1 mg/kg (Q2W Regimen)PF-06647020 2.8 mg/kg (Q2W Regimen)PF-06647020 3.2 mg/kg (Q2W Regimen)Total
Q3W Regimen18.3 ± 2.022.7 ± 2.723.6 ± 2.027.6 ± 7.725.6 ± 5.526.2 ± 4.7———25.5 ± 5.5
Q2W Regimen——————24.9 ± 7.129.9 ± 9.125.6 ± 8.827.2 ± 8.7
08

Study locations

17 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Scottsdale Healthcare Hospitals DBA HonorHealth
    Scottsdale, Arizona 85258, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Stanford Hospital and Clinics
    Stanford, California 94305, United States
  • University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • START Midwest
    Grand Rapids, Michigan 49503, United States
  • South Texas Accelerated Research Therapeutics, LLC
    San Antonio, Texas 78229, United States
  • Inova Fairfax Hospital Woodburn GYN Infusion Center
    Annandale, Virginia 22003, United States
  • Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates (MAGOPSA)
    Annandale, Virginia 22003, United States
  • Fairfax Radiological Consultants
    Fairfax, Virginia 22031, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • Inova Loudon Hospital
    Leesburg, Virginia 20176, United States
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, 28050, Spain
09

References and documents

Publications

  • Johnson M, El-Khoueiry A, Hafez N, Lakhani N, Mamdani H, Rodon J, Sanborn RE, Garcia-Corbacho J, Boni V, Stroh M, Hannah AL, Wang S, Castro H, Spira A. Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2021 Aug 15;27(16):4521-4530. doi: 10.1158/1078-0432.CCR-21-0194. Epub 2021 Jun 3. PubMed 34083236 ↗
  • Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S, Stringer-Reasor E, Lakhani N, Moreau AR, Xuan D, Li R, Powell EL, Jackson-Fisher A, Bowers M, Alekar S, Xin X, Tolcher AW, Calvo E. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin Cancer Res. 2021 Aug 15;27(16):4511-4520. doi: 10.1158/1078-0432.CCR-20-3757. Epub 2021 Jun 3. PubMed 34083232 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Nov 2019, 60 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 60 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2014
First posted
Aug 22, 2014
StartActual
Oct 17, 2014
Primary completionActual
Nov 5, 2019
CompletionActual
Nov 5, 2019
Results first posted
Dec 17, 2020
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02222922
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 22, 2014
Start date
Oct 17, 2014
Primary completion
Nov 5, 2019
Completion
Nov 5, 2019
Results posted
Dec 17, 2020
Last update
Dec 17, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluconazole · Avelumab

Start the discussion